Ana Ugarte

Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

Edurne San José‐Eneriz, Xabier Agirre, Obdulia Rabal et al. · Nature Communications · 2017 · 161 citations · Full text

Hematological Malignancy, Reversible Chemical Probes, Epigenetic Drugs +15

Trimethylamine-N-Oxide (TMAO) Predicts Cardiovascular Mortality in Peripheral Artery Disease

Carmen Roncal, E. Martínez-Aguilar, Josune Orbe et al. · Scientific Reports · 2019 · 154 citations · Full text

Decreased levels of guanosine 3′, 5′‐monophosphate (c<scp>GMP</scp>) in cerebrospinal fluid (<scp>CSF</scp>) are associated with cognitive decline and amyloid pathology in <scp>A</scp>lzheimer's disease

Ana Ugarte, Francisco J. Gil‐Bea, Carolina García et al. · Neuropathology and Applied Neurobiology · 2014 · 107 citations

A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer’s Disease Mice

Mar Cuadrado‐Tejedor, Carolina García, Juan A. Sánchez‐Arias et al. · Neuropsychopharmacology · 2016 · 103 citations · Full text

Dual Inhibitor, Synaptic Transmission, Molecular Biology +17

Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer’s Disease

Obdulia Rabal, Juan A. Sánchez‐Arias, Mar Cuadrado‐Tejedor et al. · Journal of Medicinal Chemistry · 2016 · 85 citations · Full text

Hdac Inhibitors, Drug Target, Neurochemical Biomarkers +17